Abstract
Lung cancer is the leading cause of cancer death worldwide, and most patients die of metastatic disease. Angiogenesis, namely, neovascularization from preexisting vasculature, is necessary for tumor growth in both primary and distant organs to supply oxygen and nutrition. Angiogenesis consists of sprouting and nonsprouting (the enlargement, splitting, and fusion of preexisting vessels) processes, and both can occur concurrently. The growth of non-small cell lung cancer (NSCLC), which accounts for more than 80% of all lung cancers, is usually dependent on angiogenesis, which is regulated by complex mechanisms in the presence of various angiogenesis-related molecules. Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF), is one of the most potent angiogenic molecules, while also regulating both angiogenesis and vascular permeability and hence promoting tumor progression and the development of malignant pleural effusions in NSCLC. Recent clinical trials showed that the anti-VEGF antibody bevacizumab, combined with standard first-line chemotherapy, provided a statistically and clinically significant survival advantage with tolerable toxicity. In addition, the combined use of the anti-VEGF antibody with an inhibitor of epidermal growth factor receptor (EGFR) has also shown favorable antitumor efficiency. These successes proved the validity of an antivasculature strategy for NSCLC. Furthermore, a large number of antivasculature agents have been shown to be effective against multiple targets. The efficiency of these compounds is currently being investigated in clinical trials for NSCLC.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Editorial Board of the Cancer Statistics in Japan (2001) Foundation for Promotion of Cancer Research, Tokyo
LAG Ries MP Eisner CL Kosary (2001) SEER cancer statistics review, 1973–1998 National Cancer Institute Bethesda, MD
M Fukuoka S Yano G Giaccone et al. (2003) ArticleTitleMulti-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2237–2246 Occurrence Handle10.1200/JCO.2003.10.038 Occurrence Handle1:CAS:528:DC%2BD2cXpsVGqu7w%3D Occurrence Handle12748244
N Thatcher A Chang P Parikh et al. (2005) ArticleTitleGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527–1537 Occurrence Handle10.1016/S0140-6736(05)67625-8 Occurrence Handle1:CAS:528:DC%2BD2MXhtFKhsbfP Occurrence Handle16257339
J Folkman (1971) ArticleTitleTumor angiogenesis: therapeutic implication N Engl J Med 285 182–186
RS Herbst A Onn A Sandler (2005) ArticleTitleAngiogenesis and lung cancer: prognostic and therapeutic implications J Clin Oncol 23 3243–3256 Occurrence Handle1:CAS:528:DC%2BD2MXltVWis7k%3D Occurrence Handle15886312
S Yano Y Nishioka H Goto S Sone (2003) ArticleTitleMolecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules Cancer Sci 94 479–485 Occurrence Handle1:CAS:528:DC%2BD3sXmsFWltrw%3D Occurrence Handle12824870
S Yano H Shinohara RS Herbst et al. (2000) ArticleTitleExpression of vascular endothelial growth factor is essential but not sufficient for production and growth of brain metastasis Cancer Res 60 4959–4967 Occurrence Handle1:CAS:528:DC%2BD3cXmsFWhsbk%3D Occurrence Handle10987313
IJ Fidler S Yano R Zhang et al. (2002) ArticleTitleThe seed and soil hypothesis: vascularization and brain metastases Lancet Oncol 3 53–57 Occurrence Handle10.1016/S1470-2045(01)00622-2 Occurrence Handle1:CAS:528:DC%2BD38Xhtleitb0%3D Occurrence Handle11905606
F Pezzella U Pastorino E Tagliabue et al. (1997) ArticleTitleNon-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis Am J Pathol 151 1417–1423 Occurrence Handle1:STN:280:DyaK1c%2FitlKlsg%3D%3D Occurrence Handle9358768
G Fontanini M Lucchi S Vignati et al. (1997) ArticleTitleAngiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study J Natl Cancer Inst 89 881–886 Occurrence Handle10.1093/jnci/89.12.881 Occurrence Handle1:STN:280:ByiA3sbmsFI%3D Occurrence Handle9196255
F Tanaka Y Otake K Yanagihara et al. (2001) ArticleTitleEvaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody Clin Cancer Res 7 3410–3415 Occurrence Handle1:CAS:528:DC%2BD3MXptFaisr0%3D Occurrence Handle11705856
AP Meert M Paesmans B Martin et al. (2002) ArticleTitleThe role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 87 694–701 Occurrence Handle10.1038/sj.bjc.6600551 Occurrence Handle12232748
F Tanaka Y Otake K Yanagihara et al. (2003) ArticleTitleGlomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer Cancer Res 63 6791–6794 Occurrence Handle1:CAS:528:DC%2BD3sXosVGnsr0%3D Occurrence Handle14583475
HF Dvorak (2002) ArticleTitleVascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 4368–4380 Occurrence Handle10.1200/JCO.2002.10.088 Occurrence Handle1:CAS:528:DC%2BD38Xpt1CjtL0%3D Occurrence Handle12409337
A Yuan CJ Yu SH Kuo et al. (2001) ArticleTitleVascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer J Clin Oncol 19 432–441 Occurrence Handle1:CAS:528:DC%2BD3MXhtVekt7Y%3D Occurrence Handle11208836
DO Bates TG Cui JM Doughty et al. (2002) ArticleTitleVEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma Cancer Res 62 4123–4131 Occurrence Handle1:CAS:528:DC%2BD38XlsV2ltrw%3D Occurrence Handle12124351
CL Huang D Liu J Nakano et al. (2005) ArticleTitleWnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor – an expression in non-small-cell lung cancer J Clin Oncol 23 8765–8773 Occurrence Handle16314637
S Yano Y Nishioka K Izumi et al. (1997) ArticleTitleNovel metastasis model of human lung cancer in SCID mice depleted of NK cells Int J Cancer 67 211–217
S Yano H Nokihara M Hanibuchi et al. (1997) ArticleTitleModel of malignant pleural effusion of human lung adenocarcinoma in SCID mice Oncol Res 9 573–579 Occurrence Handle1:CAS:528:DyaK1cXisVCntr8%3D Occurrence Handle9563004
T Miki S Yano M Hanibuchi et al. (2000) ArticleTitleBone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice Oncol Res 12 209–217 Occurrence Handle1:CAS:528:DC%2BD38XltlOktA%3D%3D Occurrence Handle11417746
H Yanagawa E Takeuchi Y Suzuki et al. (1999) ArticleTitleVascular endothelial growth factor in malignant pleural effusion associated with lung cancer Cancer Immunol Immunother 48 396–400 Occurrence Handle10.1007/s002620050592 Occurrence Handle1:CAS:528:DyaK1MXnsVShs7g%3D Occurrence Handle10501853
S Yano H Shinohara RS Herbst et al. (2000) ArticleTitleProduction of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells Am J Pathol 157 1893–1903 Occurrence Handle1:CAS:528:DC%2BD3MXhsVKrtQ%3D%3D Occurrence Handle11106562
JD Heiss E Papavassilous MJ Merrill et al. (1996) ArticleTitleMechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor J Clin Invest 98 1400–1408 Occurrence Handle1:CAS:528:DyaK28Xlsl2mtb0%3D Occurrence Handle8823305
KH Plate (2001) ArticleTitleFrom angiogenesis to lymphangiogenesis Nat Med 7 151–152 Occurrence Handle10.1038/84579 Occurrence Handle1:CAS:528:DC%2BD3MXhtVyht74%3D Occurrence Handle11175837
T Kajita Y Ohta K Kimura et al. (2001) ArticleTitleThe expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer Br J Cancer 85 255–260 Occurrence Handle10.1054/bjoc.2001.1882 Occurrence Handle1:CAS:528:DC%2BD3MXmtVKht7g%3D Occurrence Handle11461086
M Arinaga T Noguchi S Takeno et al. (2003) ArticleTitleClinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma Cancer (Phila) 97 457–464 Occurrence Handle1:CAS:528:DC%2BD3sXhtFGltL0%3D
J Holash PC Maisonpierre D Compton et al. (1999) ArticleTitleVessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1994–1998 Occurrence Handle10.1126/science.284.5422.1994 Occurrence Handle1:CAS:528:DyaK1MXktVWntrY%3D Occurrence Handle10373119
F Tanaka S Ishikawa K Yanagihara et al. (2002) ArticleTitleExpression of angiopoietins and its clinical significance in non-small cell lung cancer Cancer Res 62 7124–7129 Occurrence Handle1:CAS:528:DC%2BD38XpsVaht78%3D Occurrence Handle12460935
K Watanabe Y Hasegawa H Yamashita et al. (2004) ArticleTitleVasohibin as an endothelium-derived negative feedback regulator of angiogenesis J Clin Invest 114 898–907 Occurrence Handle10.1172/JCI200421152 Occurrence Handle1:CAS:528:DC%2BD2cXot12gtr8%3D Occurrence Handle15467828
LN Klapper MH Kirschbaum M Sela et al. (2000) ArticleTitleBiochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors Adv Cancer Res 77 25–79 Occurrence Handle1:CAS:528:DC%2BD3cXltl2ktw%3D%3D Occurrence Handle10549355
SJ Kim H Uehara T Karashima et al. (2003) ArticleTitleBlockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice Clin Cancer Res 9 1200–1210 Occurrence Handle1:CAS:528:DC%2BD3sXhvFKiur8%3D Occurrence Handle12631626
A Hirata S Ogawa T Kometani et al. (2002) ArticleTitleZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase Cancer Res 62 2554–2560 Occurrence Handle1:CAS:528:DC%2BD38XjtlGrsbc%3D Occurrence Handle11980649
TJ Lynch DW Bell R Sordella et al. (2004) ArticleTitleActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129–2139 Occurrence Handle10.1056/NEJMoa040938 Occurrence Handle1:CAS:528:DC%2BD2cXktF2js7c%3D Occurrence Handle15118073
AP Meert B Martin P Delmotte et al. (2002) ArticleTitleThe role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis Eur Respir J 20 975–981 Occurrence Handle10.1183/09031936.02.00296502 Occurrence Handle1:STN:280:DC%2BD38nltFCgtg%3D%3D Occurrence Handle12412692
T Kosaka Y Yatabe H Endoh et al. (2004) ArticleTitleMutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 8919–8923 Occurrence Handle10.1158/0008-5472.CAN-04-2818 Occurrence Handle1:CAS:528:DC%2BD2cXhtVOmsL3P Occurrence Handle15604253
T Kanematsu S Yano H Uehara et al. (2003) ArticleTitlePhosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients Oncol Res 13 289–298 Occurrence Handle12688680
RK Jain (2002) ArticleTitleTumor angiogenesis and accessibility: role of vascular endothelial growth factor Semin Oncol (Suppl) 16 3–9
O Belvedere F Grossi (2006) ArticleTitleLung cancer highlights from ASCO 2005 Oncologist 11 39–50 Occurrence Handle10.1634/theoncologist.11-1-39 Occurrence Handle16401712
DH Johnson L Fehrenbacher WF Novotny et al. (2004) ArticleTitleRandomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184–2191 Occurrence Handle1:CAS:528:DC%2BD2cXpsVWltrg%3D Occurrence Handle15169807
H Goto S Yano H Zhang et al. (2002) ArticleTitleActivity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice Cancer Res 62 3711–3715 Occurrence Handle1:CAS:528:DC%2BD38XltF2jtbw%3D Occurrence Handle12097279
H Goto S Yano Y Matsumori et al. (2004) ArticleTitleSensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin Clin Cancer Res 10 7671–7676 Occurrence Handle10.1158/1078-0432.CCR-04-1171 Occurrence Handle1:CAS:528:DC%2BD2cXhtVanur3M Occurrence Handle15570000
J Randal (2000) ArticleTitleAntiangiogenesis drugs target specific cancers, mechanisms J Natl Cancer Inst 92 520–522 Occurrence Handle1:STN:280:DC%2BD3c3hsFSiuw%3D%3D Occurrence Handle10749899
RS Herbst M Fukuoka J Baselga (2004) ArticleTitleGefitinib: a novel targeted approach to treating cancer Nat Rev Cancer 4 956–965 Occurrence Handle10.1038/nrc1506 Occurrence Handle1:CAS:528:DC%2BD2cXhtVarsLjJ Occurrence Handle15573117
JG Paez PA Janne JC Lee et al. (2004) ArticleTitleEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497–1500 Occurrence Handle10.1126/science.1099314 Occurrence Handle1:CAS:528:DC%2BD2cXksVGmsbs%3D Occurrence Handle15118125
F Cappuzzo FR Hirch E Rossi et al. (2005) ArticleTitleEpidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 643–655 Occurrence Handle1:CAS:528:DC%2BD2MXjvFymt70%3D Occurrence Handle15870435
F Cappuzzo E Magrini GL Ceresoli et al. (2004) ArticleTitleAkt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer J Natl Cancer Inst 96 1133–1141 Occurrence Handle1:CAS:528:DC%2BD2cXntFamsbg%3D Occurrence Handle15292385
S Kakiuchi Y Daigo N Ishikawa et al. (2004) ArticleTitlePrediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839) Hum Mol Genet 13 3029–3043 Occurrence Handle10.1093/hmg/ddh331 Occurrence Handle1:CAS:528:DC%2BD2cXhtVClu7rE Occurrence Handle15496427
J Baselga (2002) ArticleTitleWhy the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 IssueIDsuppl 4 2–8 Occurrence Handle1:CAS:528:DC%2BD38XnsFOiurw%3D Occurrence Handle12202782
S Yano RS Herbst S Shinohara et al. (2000) ArticleTitleTreatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation Clin Cancer Res 6 957–965 Occurrence Handle1:CAS:528:DC%2BD3cXisVaqurw%3D Occurrence Handle10741721
D Strumberg H Richly RA Hilger et al. (2005) ArticleTitlePhase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 965–972 Occurrence Handle1:CAS:528:DC%2BD2MXit1Ggu7c%3D Occurrence Handle15613696
SR Wedge DJ Ogilvie M Dukes et al. (2002) ArticleTitleZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645–4655 Occurrence Handle1:CAS:528:DC%2BD38XmsVShsL8%3D Occurrence Handle12183421
F Ciardiello R Caputo V Damiano et al. (2003) ArticleTitleAntitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 1546–1556 Occurrence Handle1:CAS:528:DC%2BD3sXislerur8%3D Occurrence Handle12684431
Matsumori Y, Yano S, Goto H, et al. (2006) ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res (in press)
S Yano H Muguruma Y Matsumori et al. (2005) ArticleTitleAntitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice Clin Cancer Res 11 IssueID24 pt 1 8789–8798 Occurrence Handle1:CAS:528:DC%2BD2MXhtlWrsbjE Occurrence Handle16361567
H Minami H Ebi M Tahara et al. (2002) ArticleTitleA phase I study of an oral VEGF receptor tyrosine kinase inhibitor, ZD6474, in Japanese patients with solid tumors Proc Am Soc Clin Oncol 22 194
H Hurwitz SN Holden SG Eckhaedt et al. (2002) ArticleTitleClinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors Proc Am Soc Clin Oncol 21 82a
RS Herbst DH Johson E Mininberg et al. (2005) ArticleTitlePhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer J Clin Oncol 23 2544–2555 Occurrence Handle1:CAS:528:DC%2BD2MXjvVyktLY%3D Occurrence Handle15753462
RS Kerbel (2001) ArticleTitleClinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results J Clin Oncol 19 IssueIDsuppl 18 45S–51S Occurrence Handle1:CAS:528:DC%2BD3MXnsVKqtrs%3D Occurrence Handle11560971
RS Herbst NA Mullani DW Davis et al. (2002) ArticleTitleDevelopment of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin J Clin Oncol 20 3804–3814 Occurrence Handle1:CAS:528:DC%2BD38XntVyns7o%3D Occurrence Handle12228200
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yano, S., Matsumori, Y., Ikuta, K. et al. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol 11, 73–81 (2006). https://doi.org/10.1007/s10147-006-0568-3
Received:
Issue Date:
DOI: https://doi.org/10.1007/s10147-006-0568-3